18 MONTH A1C AND WEIGHT OUTCOMES OF EXENATIDE THERAPY IN PATIENTS WITH TYPE-2 DIABETES IN A REAL-WORLD STUDY

被引：2
|
作者：
Brixner, D. [1 ]
McAdam-Marx, C. [1 ]
Ye, X. [1 ]
Misurski, D. [2 ]
Wintle, M. [3 ]
Fabunmi, R. [3 ]
机构：
[1] Univ Utah, Coll Pharm, Salt Lake City, UT 84112 USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Amylin Pharmaceut Inc, San Diego, CA USA
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73550-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A97 / A97
页数：1
相关论文
共 50 条
  • [31] Effect of weight loss on proteinuria in adults with type 2 diabetes: A real-world study
    Ren, Wenqian
    Gong, Yujia
    Zhen, Qin
    Gu, Liping
    Yang, Jiaying
    Kang, Mei
    Zhang, Aifang
    Shen, Tingting
    Wang, Yufan
    Liu, Fang
    Li, Na
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 206
  • [32] Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy
    Davis, Keith L.
    Tangirala, Muralikrishna
    Meyers, Juliana L.
    Wei, Wenhui
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (09) : 1083 - 1091
  • [33] Real-World Outcomes of Initiating Injectable Therapy With Insulin Glargine or Liraglutide Among Patients With Type 2 Diabetes
    Levin, Philip
    Wei, Wenhui
    Vlajnic, Aleksandra
    Pan, Chunshen
    Xie, Lin
    Lin, Jay
    Baser, Onur
    DIABETES, 2012, 61 : A4 - A4
  • [34] A1C AND WEIGHT OUTCOMES FOLLOWING 6 MONTHS OF ANALOG BASAL INSULIN IN INSULIN NAIVE PATIENTS WITH TYPE-2 DIABETES IN AN AMBULATORY CARE SETTING
    McAdam-Marx, C.
    Brixner, D.
    Ye, X.
    Misurski, D.
    Fabunmi, R.
    VALUE IN HEALTH, 2009, 12 (03) : A97 - A97
  • [35] REAL-WORLD FEASIBILITY OF THE HEMOGLOBIN A1C TARGET OF ≤7.0% IN TYPE 1 DIABETES: A RETROSPECTIVE, POPULATION-BASED COHORT STUDY
    Weisman, A.
    Booth, G.
    Everett, K.
    Tomlinson, G.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A94 - A95
  • [36] IS MORE ALWAYS BETTER? A REAL-WORLD DATA ANALYSIS OF HEMOGLOBIN A1C DATA IN PATIENTS WITH DIABETES
    Liu, Y.
    Ross, R.
    Diakun, D.
    Lew, C.
    Princic, N.
    Palmer, L.
    VALUE IN HEALTH, 2024, 27 (06) : S380 - S380
  • [37] Switching from insulin to dulaglutide therapy in patients with type 2 diabetes: A real-world data study
    Lee, Jiwoo
    Kim, Hwi Seung
    Jung, Chang Hee
    Park, Joong-Yeol
    Lee, Woo Je
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2021, 37 (08)
  • [38] Real-world six month outcomes of patients initiating exenatide in a primary care electronic medical record database
    Brixner, D.
    McAdam-Marx, C.
    Ye, X.
    Boye, K. S.
    Schroeder, B.
    Fabunmi, R.
    VALUE IN HEALTH, 2008, 11 (03) : A17 - A17
  • [39] Estimating the Potential Cardiovascular Benefit of A1c Reduction and Weight Loss in Patients with Type 2 Diabetes Treated with Exenatide for at Least Three Years
    Best, Jennie H.
    Herman, William H.
    Wintle, Matthew
    DIABETES, 2009, 58 : A316 - A316
  • [40] REAL-WORLD GLYCEMIC OUTCOMES OF PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES ACHIEVED THROUGH A FULLY VIRTUAL INTEGRATED DIABETES PROGRAM
    Wu, C.
    Reddy, S.
    Hsieh, J.
    Jose, A.
    Rautela, S.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A69 - A70
12345